Effect of convalescent blood products for patients with severe acute respiratory infections of viral etiology: a systematic review and meta-analysis

From December 2019 until now, more than 29 million people have been diagnosed with Coronavirus Disease 2019 (COVID-19) worldwide in the present pandemic, and the overall mortality is 3.1% (Maps& Trends - Johns Hopkins Coronavirus Resource Center, 2020). The disease progresses rapidly in patients infected with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), and those patients could suffer from acute respiratory distress syndrome (ARDS), acute respiratory failure, multi-organ dysfunction or even death in a short period (Chen et al., 2020; Yang et al., 2020; Guan et al., 2020a; Wang et al., 2020).
Source: International Journal of Infectious Diseases - Category: Infectious Diseases Authors: Source Type: research